Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Routine tests undertaken by women dropped by 35% in 2020
The availability of advanced SLED dialysis for critical patients, Plasmapheresis, CRRT machines along with ICCU dialysis complete the centre in every way
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
The new centre will comprise a team of 50 highly experienced specialists
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Subscribe To Our Newsletter & Stay Updated
